Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urodynamic evaluation of silodosin 8 mg once daily in benign prostatic obstruction
2015-002277-38Phase 4Completed
- Sponsor
- Recordati SpA
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of silodosin in benign prostatic hyperplasia (BPH) and benign prostatic obstruction (BPO), sponsored by Recordati SpA. Primary endpoint: Change from baseline in Bladder Outlet Obstruction Index (BOOI). Started Dec 2017; status: completed.
02
Drugs
silodosin
03
Conditions
benign prostatic hyperplasia (BPH)benign prostatic obstruction (BPO)
Beyond the preview
Go deeper on 2015-002277-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002277-38.